Scarica l'app Stockscreener
166.91
0.76%
-1.27
Pre-mercato:
166.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics Incorporated Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
What analysts say about Quest Diagnostics Incorporated stockTriple-digit return opportunities - jammulinksnews.com
Quest Diagnostics (DGX) Maintains Neutral Rating Amid Slight PT Adjustment | DGX Stock News - GuruFocus
Quest Diagnostics: UBS Keeps Neutral Rating, Lowers PT to $175 from $176 - AInvest
Quest Diagnostics (DGX) Faces Slight Price Target Adjustment by UBS | DGX Stock News - GuruFocus
What drives Quest Diagnostics Incorporated stock priceHigh-octane investment gains - Jammu Links News
11th Circ. Says Ex-Quest Diagnostics Worker's FCA Suit Fails - Law360
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Quest Lab Worker Fails to Revive Billing Fraud Suit on Appeal - Bloomberg Law News
Quest to offer Fujirebio’s FDA-cleared Alzheimer’s blood test - MedTech Dive
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Quest Diagnostics launches test for Oropouche virus amid spread in Americas - Investing.com Canada
Quest Diagnostics (DGX) Launches Oropouche Virus Test | DGX Stoc - GuruFocus
Quest Diagnostics Introduces Testing for Oropouche Virus - MarketScreener
First-Ever Commercial Test for Dangerous Oropouche Virus Launches as Disease Spreads in Americas - Stock Titan
Quest Diagnostics: Buy Into Future Patient Demand, Undervalued Price Today (DGX) - Seeking Alpha
Despite Slump, Options Traders May Be Seeing Something With Quest Diagnostics (DGX) - barchart.com
Quest Diagnostics (DGX) Develops MCaST Blood Test with MD Anderson Cancer Center - Yahoo Finance
Quest Diagnostics Stock Drops 2.51% Amid Analyst Upgrade - AInvest
Quest Diagnostics Surges to 417th in Trading Volume with 2.25 Billion Shares Traded - AInvest
Quest Diagnostics (DGX) Launches FDA-Approved Alzheimer's Test - GuruFocus
Quest Diagnostics to offer Fujirebio Alzheimer's diagnostic test - Seeking Alpha
Quest Diagnostics Launches Revolutionary FDA-Cleared Blood Test to Detect Early Alzheimer's with 97% Accuracy - Stock Titan
Leerink Partners Adjusts PT on Quest Diagnostics to $192 From $189, Maintains Outperform Rating - MarketScreener
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It? - Nasdaq
Ex-Dividend Reminder: Edison International, Quest Diagnostics and Cousins Properties - Nasdaq
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant - TradingView
Quest Diagnostics tops NJ life sciences employer list - NJBIZ
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now? - Nasdaq
What to Expect From Quest Diagnostics' Q2 2025 Earnings Report - inkl
What To Expect From Quest Diagnostics' Q2 2025 Earnings Report - barchart.com
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
DGX Stock Up on New Blood Test Development Deal With MD Anderson - MSN
Quest Diagnostics Transforms Healthcare Access: $13M in Grants, 1M Free Tests, and 50 New Diagnostic Services - Stock Titan
Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025 – Company Announcement - Financial Times
Is Quest Diagnostics Stock Outperforming the Nasdaq? - MSN
Is Quest Diagnostics Stock Outperforming The Nasdaq? - barchart.com
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Quest Diagnostics stock hits all-time high of $180.11 By Investing.com - Investing.com Canada
Quest partners with MD Anderson to develop cancer risk blood test - MedTech Dive
Quest Diagnostics and University of Texas want to promote more cancer screenings - Mugglehead Magazine
Fecal Immunochemical Diagnostic Test (FIT) Market Top - openPR.com
Quest Diagnostics (DGX) Collaborates with MD Anderson for Cancer Risk Test Development | DGX Stock News - GuruFocus
Quest Diagnostics New Blood Test Could Transform Early Cancer Detection for 9 Major Cancers - Stock Titan
Quest Diagnostics Incorporated : The stock forcefully approaches new pivot levels - MarketScreener
Quest Diagnostics (DGX) Stock Analysis: Navigating a 5.5% Upside with Strong Revenue Growth - DirectorsTalk Interviews
Transcript : Quest Diagnostics Incorporated Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - marketscreener.com
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term - Yahoo Finance
Testing & Diagnostics Services Stocks Q1 Teardown: Quest (NYSE:DGX) Vs The Rest - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Participates in Upcoming Oppenheimer Mee - GuruFocus
Quest Diagnostics (DGX) Participates in Upcoming Oppenheimer Meeting | DGX Stock News - GuruFocus
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick? - The Globe and Mail
Is Wall Street Bullish or Bearish on Quest Diagnostics Stock? - inkl
Is Wall Street Bullish Or Bearish On Quest Diagnostics Stock? - Barchart.com
Quest Diagnostics' $4M Rest Break Settlement Gets Initial OK - Law360
Quest Diagnostics (DGX) Announces Results of 2025 Annual Meeting of Stockholders - GuruFocus
3.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):